ranitidine

(redirected from Ranitidine bismuth citrate)
Also found in: Dictionary, Thesaurus.
Related to Ranitidine bismuth citrate: Pylorid

ranitidine

 [rah-nit´ĭ-dēn]
an antagonist of histamine H2receptors, used as the hydrochloride salt to inhibit stomach hydrochloric acid secretion in treatment of peptic ulcers, gastroesophageal reflux, and conditions of gastric hypersecretion, administered orally, intramuscularly, or intravenously.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

ranitidine

(rə-nĭt′ĭ-dēn′)
n.
A histamine receptor antagonist, C13H22N4O3that inhibits gastric acid secretion and is used primarily to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

ranitidine

Zantac Therapeutics An H2-receptor antagonist used to treat peptic ulcer disease, gastric and duodenal ulcers, esophageal erosions, GERD, and conditions–eg, Zollinger-Ellison disease and systemic mastocytosis in which there is ↑ H2 activity due to blocking of the binding of histamine to H2 receptors, resulting in ↓ intracellular concentration of cAMP and acid secretion by gastric parietal cells Adverse reactions Diarrhea, headache, fatigue, myalgia, constipation, confusion, agranulocytosis, gynecomastia, impotence, allergic reactions, tachycardia, arrhythmias, interstitial nephritis, etc. See H2 blockers, Histamine receptor antagonists.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

ranitidine

An H-2 (histamine-2) receptor antagonist drug used to reduce acid secretion in cases of peptic ulceration. A band name is Zantac. See also RANTITIDINE BISMUTH CITRATE.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Seven-day triple therapy of ranitidine bismuth citrate + clarithromycin + metronidazole or amoxicillin For these therapies, a high-quality systematic review of 8 studies reported eradication rates of 81% (95% CI, 77%-84%) with amoxicillin and 88% (95% CI, 85%-90%) with metronidazole.
Ranitidine bismuth citrate (RBC) 400 mg BID + clarithromycin 500 mg TID x 2wks then RBC 400 mg BID x 2 wks
PPI quadruple therapy or a regimen including furazolidone (a monoamine oxidase inhibitor) may serve as second-line treatment for eradication of initial failures and in case of metronidazole resistance.[18,19] Studies using ranitidine bismuth citrate in place of PPIs have also shown comparable results.